Ophthopedia

@ophthalmology.bsky.social

Latest updates on publications and news from #ophthalmology and #visionscience. Curated by @rohanbir.bsky.social. Let the #OphthoSky begin! :)

Ophthopedia Update: Multimodal imaging of Yasunari nodules in neurofibromatosis type 1: Eye, Published online: 05 August 2026; doi:10.1038/s41433-026-04799-1Multimodal imaging of Yasunari nodules in neurofibromatosis type 1 #Ophthalmology #Eye #Ophthotwitter

Multimodal imaging of Yasunari nodules in neurofibromatosis type 1

Eye, Published online: 05 August 2026; doi:10.1038/s41433-026-04799-1Multimodal imaging of Yasunari nodules in neurofibromatosis type 1

dlvr.it

Ophthopedia Update: Artificial intelligence is here to stay: the role of scientific etiquette: Eye, Published online: 05 August 2026; doi:10.1038/s41433-026-04801-wArtificial intelligence is here to stay: the role of scientific etiquette #Ophthalmology #Eye #Ophthotwitter

Artificial intelligence is here to stay: the role of scientific etiquette

Eye, Published online: 05 August 2026; doi:10.1038/s41433-026-04801-wArtificial intelligence is here to stay: the role of scientific etiquette

dlvr.it

Ophthopedia Update: The cataract that wasn’t: aphakic posterior capsular fibrosis with anterior chamber silicone oil: Eye, Published online: 05 August 2026; doi:10.1038/s41433-026-04785-7The cataract that wasn’t: aphakic posterior capsular fibrosis with anterior… #Ophthalmology #Eye #Ophthotwitter

The cataract that wasn’t: aphakic posterior capsular fibrosis with anterior chamber silicone oil

Eye, Published online: 05 August 2026; doi:10.1038/s41433-026-04785-7The cataract that wasn’t: aphakic posterior capsular fibrosis with anterior chamber silicone oil

dlvr.it

Ophthopedia Update: Nd:YAG laser membranolysis of a fibrin membrane occluding an AADI-250 tube: Eye, Published online: 05 August 2026; doi:10.1038/s41433-026-04783-9Nd:YAG laser membranolysis of a fibrin membrane occluding an AADI-250 tube #Ophthalmology #Eye #Ophthotwitter

Nd:YAG laser membranolysis of a fibrin membrane occluding an AADI-250 tube

Eye, Published online: 05 August 2026; doi:10.1038/s41433-026-04783-9Nd:YAG laser membranolysis of a fibrin membrane occluding an AADI-250 tube

dlvr.it

Ophthopedia Update: Image-based AI for Automated Diagnosis and Clinical Activity Grading in Thyroid Eye Disease: A Systematic Review and Meta-analysis: To evaluate diagnostic accuracy of image-based AI for thyroid eye disease (TED) diagnosis and clinical… #Ophthalmology #ophthotwitter #eyecare

Image-based AI for Automated Diagnosis and Clinical Activity Grading in Thyroid Eye Disease: A Systematic Review and Meta-analysis

To evaluate diagnostic accuracy of image-based AI for thyroid eye disease (TED) diagnosis and clinical activity grading (CAS ≥3 vs

dlvr.it

Ophthopedia Update: Risk of Pediatric Eye Disease in Children with Neurodevelopmental and Behavioral Disorders in the United States: To evaluate the association of neurodevelopmental disorders (NDDs) and behavioral disorders with amblyopia, myopia,… #Ophthalmology #ophthotwitter #eyecare

Risk of Pediatric Eye Disease in Children with Neurodevelopmental and Behavioral Disorders in the United States

To evaluate the association of neurodevelopmental disorders (NDDs) and behavioral disorders with amblyopia, myopia, strabismus, and strabismus surgery rates.

dlvr.it

Ophthopedia Update: Weekly Journal Update — August 5, 2026: Increased IOP in wind instrument players, possible mechanism of cystoid macular edema in retinitis pigmentosa, phase 1 study of topical laquinimod eyedrops, transient vision loss and risk of major cardiovascular… #Ophthalmology #News

Weekly Journal Update — August 5, 2026

Increased IOP in wind instrument players, possible mechanism of cystoid macular edema in retinitis pigmentosa, phase 1 study of topical laquinimod eyedrops, transient vision loss and risk of major cardiovascular events, ocular symptoms of Loeys-Dietz syndrome.

dlvr.it

Ophthopedia Update: Integrating opportunistic ocular diseases screening into general health examination in Chinese: a multicentre study: Background/aims Cost-effective screening models for ocular diseases in large populations remain a critical challenge for… #Ophthalmology #Ophthotwitter #BJO

Integrating opportunistic ocular diseases screening into general health examination in Chinese: a multicentre study

Background/aims Cost-effective screening models for ocular diseases in large populations remain a critical challenge for blindness prevention. Our preliminary study demonstrated the feasibility of opportunistic glaucoma screening integrated into general health examinations. This study aimed to evaluate the efficacy of this model for fundus disease screening in a multicentre, large-sample Chinese population.Methods This study was conducted in five health examination centres from four provinces of China. Chinese participants aged ≥18 years undergoing routine health examinations were invited to complete bilateral presenting visual acuity and non-mydriatic fundus photography. Fundus photography was assessed by two experienced graders. Proportion of fundus diseases/changes were calculated. Costs for the screening were also assessed.Results A total of 63 935 eligible participants (age 45.4±14.0 years, 51.3% men) were enrolled. The top five diseases/changes were non-macular drusen (8.80%), macular degeneration (6.30%), glaucoma suspect (5.54%), epiretinal membrane (3.92%) and diabetic retinopathy (3.89%). The proportion of low vision and blindness in the total population was 5.85% and 0.15%, respectively. The top five diseases/changes with vision impairment were retinitis pigmentosa (18.18%), myopic retinopathy (16.52%), macular hole (11.76%), non-glaucomatous optic neuropathy (7.25%) and glaucomatous optic neuropathy (6.37%). The unit cost of screening a single case and an ocular disease suspect was US$22.2 (US$15.7 to US$26.7) and US$83.2 (US$58.7 to US$99.9), respectively.Conclusions This health examination centre-based screening model is feasible, effective and affordable for detecting multiple fundus diseases in large populations. As the model is promoted and its coverage expands, screening costs may be further reduced.

dlvr.it

Ophthopedia Update: No-History IOL Power Calculation After Myopic Laser Vision Correction: A Multicenter Retrospective Database Study of 14 Formulas With and Without Posterior Corneal Curvature: To investigate intraocular lens (IOL) power formulas in eyes… #Ophthalmology #Ophthotwitter #Scicomm

No-History IOL Power Calculation After Myopic Laser Vision Correction: A Multicenter Retrospective Database Study of 14 Formulas With and Without Posterior Corneal Curvature

To investigate intraocular lens (IOL) power formulas in eyes with prior myopic laser vision correction (M-LVC).

dlvr.it

Ophthopedia Update: Cancer Type–Specific Risks of Retinal Vascular Occlusion: A Nationwide Population-Based Study: To evaluate the incidence and risk of retinal artery occlusion (RAO) and retinal vein occlusion (RVO) in cancer survivors across anatomical… #Ophthalmology #Retina #Ophthotwitter

Cancer Type–Specific Risks of Retinal Vascular Occlusion: A Nationwide Population-Based Study

To evaluate the incidence and risk of retinal artery occlusion (RAO) and retinal vein occlusion (RVO) in cancer survivors across anatomical cancer subgroups.

dlvr.it

Ophthopedia Update: Optimising the patient pathway for macular conditions requiring intravitreal injections: Macular disease is the leading cause of vision loss in the United Kingdom, affecting nearly 1.5 million people. Vascular endothelial growth factor (VEGF) has a major role in the onset and…

Optimising the patient pathway for macular conditions requiring intravitreal injections

Macular disease is the leading cause of vision loss in the United Kingdom, affecting nearly 1.5 million people. Vascular endothelial growth factor (VEGF) has a major role in the onset and progression of vision-threatening macular conditions such as neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion. Anti-VEGF treatments, given by intravitreal injection, can prevent vision loss and may improve vision but must be started quickly before sight loss is irreversible. Informed by an observational study using Hospital Episode Statistics and the Emergency Care Data Set in England and a Costed Integrated Patient Scenario, we identify issues within the current pathway in England. Our key recommendations to optimise care and improve patient outcomes include: (1) increasing public awareness of macular disease to reduce late presentation; (2) ensuring the right patients are seen in the right place at the right time by improving quality and priority of optometrist referrals and by specialists directing patients with conditions such as diabetes and hypertension to community optometrists in the first instance; (3) planning for current and future demand and capacity using innovative solutions to manage expected increases in medical retina conditions and (4) ensuring patient-centred care. Our evidence should encourage National Health Service organisations at all levels to review macular disease pathways to address immediate issues and plan for the future. A shift in care delivery is needed, embracing scalable sustainable solutions, earlier diagnosis and treatment, improved access to more durable therapies, wider adoption of digital technologies and care closer to home.

dlvr.it

Ophthopedia Update: Risk of glaucoma among patients using tadalafil for lower urinary tract symptoms: a multinational cohort study: Aim To evaluate the association between tadalafil use for lower urinary tract symptoms (LUTS) and the risk of developing… #Ophthalmology #Ophthotwitter #BJO

Risk of glaucoma among patients using tadalafil for lower urinary tract symptoms: a multinational cohort study

Aim To evaluate the association between tadalafil use for lower urinary tract symptoms (LUTS) and the risk of developing glaucoma.Methods This multinational, retrospective cohort study was conducted using the TriNetX database. Men aged ≥40 years with a history of LUTS were enrolled between 2012 and 2022. Individuals with a history of glaucoma prior to cohort entry were excluded. Participants were categorised into the tadalafil group and the non-phosphodiesterase type 5 inhibitor (non-PDE5i) group. Propensity score matching (1:1) was conducted to balance age, race, comorbidities, renal function and concomitant medications. Hazard ratios (HRs) were estimated for incident glaucoma of different subtypes and initiation of glaucoma treatment.Results The cohort included 36 927 tadalafil users and 36 927 matched non-PDE5i users. Up to 5 years, tadalafil use was associated with an increased risk of glaucoma compared with non-PDE5i use (HR 1.22; 95% CI 1.12 to 1.33). Elevated risks were observed for ocular hypertension (HR 1.32; 95% CI 1.06 to 1.65), primary open-angle glaucoma (HR 1.33; 95% CI 1.05 to 1.67) and initiation of glaucoma treatment (HR 1.33; 95% CI 1.20 to 1.47). No significant associations were found for low-tension or primary angle-closure glaucoma. Tadalafil users had a higher 5-year cumulative incidence than non-users (3.93% vs 3.16%; p50 years, white population and across comorbidities, remaining robust to 1-, 3- and 6-month lag times.Conclusions Tadalafil was associated with increased risk of glaucoma compared with non-PDE5i in males with LUTS. Ophthalmic evaluation and follow-up may be considered, particularly in patients with risk factors for glaucoma.

dlvr.it

Ophthopedia Update: Response to: ‘Comment on: ‘Patient experience of and barriers to the eye examination”: Eye, Published online: 04 August 2026; doi:10.1038/s41433-026-04790-wResponse to: ‘Comment on: ‘Patient experience of and barriers to the eye examination” #Ophthalmology #Eye #Ophthotwitter

Response to: ‘Comment on: ‘Patient experience of and barriers to the eye examination”

Eye, Published online: 04 August 2026; doi:10.1038/s41433-026-04790-wResponse to: ‘Comment on: ‘Patient experience of and barriers to the eye examination”

dlvr.it